BerandaEVT • FRA
add
Evotec SE
Tutup sebelumnya
€5,85
Rentang hari
€5,82 - €5,99
Rentang tahun
€5,12 - €21,70
Kapitalisasi pasar
1,03Â M EUR
Volume Rata-Rata
9,84Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
ETR
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(EUR) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 182,12Â jt | 6,96% |
Biaya operasional | 51,89Â jt | -33,04% |
Laba bersih | -94,93Â jt | -535,89% |
Margin laba bersih | -52,13 | -494,41% |
Penghasilan per saham | -0,18 | -361,25% |
EBITDA | -11,75Â jt | -33,60% |
Tarif pajak efektif | 9,12% | — |
Neraca
Total aset
Total liabilitas
(EUR) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 298,87Â jt | -51,86% |
Total aset | 2,00Â M | -13,14% |
Total liabilitas | 987,43Â jt | -12,38% |
Total ekuitas | 1,01 M | — |
Saham yang beredar | 177,30 jt | — |
Harga terhadap nilai buku | 1,03 | — |
Tingkat pengembalian aset | -4,30% | — |
Tingkat pengembalian modal | -5,61% | — |
Arus Kas
Perubahan kas bersih
(EUR) | Jun 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -94,93Â jt | -535,89% |
Kas dari operasi | -50,42Â jt | -539,86% |
Kas dari investasi | -31,28Â jt | -179,43% |
Kas dari pembiayaan | -119,04Â jt | -1.326,96% |
Perubahan kas bersih | -206,43Â jt | -540,82% |
Arus kas bebas | -31,66 jt | — |
Tentang
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Didirikan
1993
Situs
Karyawan
5.022